Literature DB >> 11699927

Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum.

A Balla1, A Hashim, S Burch, D C Javitt, A Lajtha, H Sershen.   

Abstract

Phencyclidine (PCP) administration in rodents has been used to model aspects of schizophrenia. One aspect of such treatment has been the enhancement of amphetamine-induced increase of dopamine in the prefrontal cortex and striatum. To further characterize this mechanism rats were treated for 2 weeks with continuous PCP (15 mg/kg per day via Alzet minipump). Rats were implanted with a microdialysis probe into the prefrontal cortex (PFC) or striatum. Amphetamine was administered locally via the dialysis probe during one collection period and changes in extracellular dopamine were monitored. The effect of local administration of the dopamine uptake blocker nomifensine was also measured. Amphetamine (10 microM) and nomifensine (10 microM) increased the level of dopamine in both the PFC and striatum. PCP administration did not alter the response to amphetamine or nomifensine in the PFC, but reduced this response about 2-fold in striatum. To examine effects of continuous PCP administration on dopamine autoreceptor function, release of [3H]dopamine in response to electrical stimulation and in the presence of a dopamine agonist or antagonist was tested in striatal and prefrontal cortical tissue. Autoreceptor responses were similar in control and PCP-treated tissues. We conclude that the brain region-specific enhancement of dopamine release by peripheral amphetamine administration in rats after PCP is not likely mediated by alterations in the dopamine autoreceptors or changes in the dopamine transporter. The selective local responses of amphetamine indicates heterogeneous regional effects of continuous PCP on NMDA receptor function; effects that influence both regional excitatory responses and the overall dynamics of tonic excitatory/inhibitory inputs to the PFC and striatum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699927     DOI: 10.1023/a:1012396820510

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  19 in total

1.  Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat.

Authors:  J D Jentsch; A Tran; D Le; K D Youngren; R H Roth
Journal:  Neuropsychopharmacology       Date:  1997-08       Impact factor: 7.853

2.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

3.  Chronic cocaine treatment impairs the regulation of synaptosomal 3H-DA release by D2 autoreceptors.

Authors:  S J Yi; K M Johnson
Journal:  Pharmacol Biochem Behav       Date:  1990-07       Impact factor: 3.533

4.  Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats.

Authors:  J D Jentsch; L Dazzi; J P Chhatwal; C D Verrico; R H Roth
Journal:  Neurosci Lett       Date:  1998-12-24       Impact factor: 3.046

5.  Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex.

Authors:  N Lindefors; S Barati; W T O'Connor
Journal:  Brain Res       Date:  1997-06-13       Impact factor: 3.252

6.  Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis.

Authors:  K Nishijima; A Kashiwa; A Hashimoto; H Iwama; A Umino; T Nishikawa
Journal:  Synapse       Date:  1996-04       Impact factor: 2.562

7.  Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter.

Authors:  S R Sesack; V A Hawrylak; C Matus; M A Guido; A I Levey
Journal:  J Neurosci       Date:  1998-04-01       Impact factor: 6.167

8.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.

Authors:  B Adams; B Moghaddam
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

10.  Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum.

Authors:  D King; J M Finlay
Journal:  Brain Res       Date:  1995-07-10       Impact factor: 3.252

View more
  4 in total

Review 1.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 2.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

3.  Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate.

Authors:  Stephan Bickel; Daniel C Javitt
Journal:  Behav Brain Res       Date:  2009-05-09       Impact factor: 3.332

4.  Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia.

Authors:  Andrea Balla; Samantha Schneider; Henry Sershen; Daniel C Javitt
Journal:  Eur Neuropsychopharmacol       Date:  2012-05-05       Impact factor: 4.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.